Global Regenerative Medicine Market Market Outlook 2030: Industry Insights & Opportunity Evaluation, 2019-2030

$5,000$10,000

Regenerative Medicine Market : Segmented by Product Type (Stem cell therapy, Biomaterial, Tissue Engineering and Others); by Application (Bone Graft substitutes, Osteoarticular Diseases, Dermatology, Cardiovascular, Central Nervous System, Others); By End-User (Hospitals, Special Clinics, Others) and Region – Global Analysis of Market Size, Share & Trends for 2019–2020 and Forecasts to 2030

Clear
SKU: FPG0679 Category: Tag:

Description

Regenerative Medicine Market

Global Regenerative Medicine Market to surpass USD 131.08 billion by 2030 from USD 16.27 billion in 2020 at a CAGR of 23.20% in the coming years, i.e., 2021-30.

Product Overview
Regenerative medicine is a field of biomedical research that focuses on regenerating the structure and function of damaged tissues and organs. It entails the use of stem cells that are created in labs and then safely transplanted into the body to regenerate damaged bones, cartilage, blood vessels, and organs. Cellular and acellular regeneration medications are often utilized in clinical treatment techniques such as cell, immunomodulation, and tissue engineering. They have the potential to cure a variety of chronic illnesses, including Alzheimer’s disease, Parkinson’s disease, cardiovascular disorders (CVDs), osteoporosis, and spinal cord injuries. Regenerative medicine reduces the chance of organ rejection by the body after transplantation and speeds up the patient’s recovery.

Market Highlights
Global Regenerative Medicine Market is expected to project a notable CAGR of 23.20% in 2030
One of the main reasons driving the market’s growth is the rising incidence of chronic medical conditions and genetic diseases throughout the world. In addition, the growing elderly population, which is susceptible to musculoskeletal, oncological, dermatological, and cardiological illnesses, is driving market expansion. As a result, the broad acceptance of organ transplantation is also helping to drive market development. Other growth-inducing variables include technological breakthroughs in cell-based treatments, such as the development of 3D bioprinting techniques and the use of artificial intelligence (AI) in the manufacture of regenerative medicines.
Recent highlights in the Global Regenerative Medicine Market
In February 2020, AmnioExcel Plus Placental allograft membrane was released by Integra Lifesciences (US).
In November 2019, Stryker Corporation (US) purchased Wright Medical (US) to expand its product portfolio.

Global Regenerative Medicine Market: Segments
Dermatology segment to grow with the highest CAGR during 2020-30
Global Regenerative Medicine Market is segmented by Application into Bone Graft substitutes, Osteoarticular Diseases, Dermatology, Cardiovascular, Central Nervous System, Others. Among these Dermatology is expected to have the highest growth in the forecast period and this significant contribution is due to the availability of simple grafting methods for dermatological wounds and illnesses. Skin supplies numerous types of stem cells from its various layers, as it is an organ with excellent cell replication properties. As a result, a wide range of treatments are available, ranging from patches to treat minor injuries to matrix and grafts for chronic wounds and burns. As a result, over the projected period, the sector is likely to continue to dominate the market.
Tissue engineering segment to grow with the highest CAGR during 2020-30
Global Regenerative Medicine is divided by Product into Stem cell therapy, Biomaterial, Tissue Engineering, Others. Among these Tissue Engineering segment held the majority share in the Regenerative Medicine Market in 2019. The increased investment for R&D of regenerative medicine goods and therapies, as well as the increasing use of tissue-engineered products for the treatment of chronic wounds and musculoskeletal problems, are the key drivers driving the expansion of this sector.

Market Dynamics
Drivers
Growing prevalence of chronic diseases, genetic disorders, and cancer
The incidence and prevalence of chronic diseases such as cardiovascular disease, cancer, diabetes, ulcers, and genetic abnormalities such as cystic fibrosis have grown dramatically during the last several decades all across the world. Diabetes and obesity can increase the occurrence and complexity of wounds such as infections, ulcerations (leg or foot ulcers), and surgical wounds, all of which necessitate care and result in astronomical medical costs.
Restraint
High-cost cell and gene therapies
For patients suffering from terminal diseases and severe disorders, cell and gene treatments offer tremendous scientific and medical development. These treatments are assisting in the transformation of how illnesses are treated and may be cured. Furthermore, such therapies will ultimately allow doctors and medical professionals to inject genes/cells into patients instead of using a series of medicines and undergoing several procedures. Despite the fact that these therapies are lifesavers and more successful than traditional treatments, demand for these therapies is lower than anticipated. This is due to the high prices of these therapies as well as the difficulties in securing reimbursements and coverage.

Global Regenerative Medicine Market: Key Players
3M
Company Overview, Business Strategy, Key Product Offerings, Financial Performance, Key Performance Indicators, Risk Analysis, Recent Development, Regional Presence, SWOT Analysis
Novartis AG
Aspect Biosystems
Kite Pharma
Misonix
Takeda Pharmaceutical Company Limited
Tego Science
Vericel Corporation
Smith & Nephew plc
Androgen Co., Ltd
Bluebird bio

Global Regenerative Medicine Market: Regions
Global Regenerative Medicine Market is segmented based on regional analysis into five major regions. These include North America, Latin America, Europe, Asia Pacific, and the Middle East, and Africa. Global Regenerative Medicine in North America held the largest market share in the year 2019. The rise in stem cell banking, tissue engineering, and drug discovery in the region, as well as the expansion of the healthcare sector and the high adoption of stem cell therapy and cell immunotherapies for the treatment of cancer and chronic diseases, have all contributed to the growth of the North American regenerative medicine market.
Global Regenerative Medicine Market is further segmented by region into:
North America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United States and Canada
Latin America Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – Mexico, Argentina, Brazil, and Rest of Latin America
Europe Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – United Kingdom, France, Germany, and Rest of Europe
Asia Pacific Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – China, Japan, Australia, and Rest of APAC
The Middle East and Africa Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR – North Africa, Israel, GCC, South Africa, and Rest of MENA

Global Regenerative Medicine
report also contains analysis on:
Regenerative Medicine Segments:
By Product Type
Stem cell therapy
Biomaterial
Tissue Engineering
Others
By Application
Bone Graft substitutes
Osteoarticular Diseases
Dermatology
Cardiovascular
Central Nervous System
Others
By End-User
Hospitals
Special Clinics
Others
Regenerative Medicine Market Dynamics
Regenerative Medicine Market Size
Supply & Demand
Current Market Trends/Issues/Challenges
Competition & Companies Involved in the Market
Value Chain of the Market
Market Drivers and Restraints
Regenerative Medicine Market
Report Scope and Segmentation

Report Attribute Details
Market size value in 2021 USD 20.02 billion
Revenue forecast in 2030 USD 131.08 billion
Growth Rate CAGR of 23.20% from 2021 to 2030
Base year for estimation 2020
Quantitative units Revenue in USD billion and CAGR from 2021 to 2030
Report coverage Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments covered Product Type, Application, End-Use, and Region
Regional scope North America; Europe; Asia Pacific; Latin America; Middle East & Africa (MEA)
Key companies profiled 3M, Novartis AG, Aspect Biosystems, Kite Pharma, Misonix, Takeda, Pharmaceutical Company Limited, Tego Science, Vericel Corporation, Smith & Nephew plc, Anterogen Co., Ltd, Bluebird bio and Other Prominent Players.

Frequently Asked Questions
How big is the Regenerative Medicine market?
What is the Regenerative Medicine market growth?
Which segment accounted for the largest Regenerative Medicine market share?
Who are the key players in the Regenerative Medicine market?
What are the factors driving the Regenerative Medicine market?

Additional information

Publisher

Geography Covered

Date Published

,

Pages

Format

Table of Contents

Contents
1. Executive Summary
2. Global Regenerative Medicine Market
2.1. Product Overview
2.2. Market Definition
2.3. Segmentation
2.4. Assumptions and Acronyms
3. Research Methodology
3.1. Research Objectives
3.2. Primary Research
3.3. Secondary Research
3.4. Forecast Model
3.5. Market Size Estimation
4. Average Pricing Analysis
5. Macro-Economic Indicators
6. Market Dynamics
6.1. Growth Drivers
6.2. Restraints
6.3. Opportunity
6.4. Trends
7. Correlation & Regression Analysis
7.1. Correlation Matrix
7.2. Regression Matrix
8. Recent Development, Policies & Regulatory Landscape
9. Risk Analysis
9.1. Demand Risk Analysis
9.2. Supply Risk Analysis
10. Global Regenerative Medicine Market Analysis
10.1. Porters Five Forces
10.1.1. Threat of New Entrants
10.1.2. Bargaining Power of Suppliers
10.1.3. Threat of Substitutes
10.1.4. Rivalry
10.2. PEST Analysis
10.2.1. Political
10.2.2. Economic
10.2.3. Social
10.2.4. Technological
11. Global Regenerative Medicine Market
11.1. Market Size & forecast, 2020A-2030F
11.1.1. By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
11.1.2. By Volume (Million Units) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12. Global Regenerative Medicine Market: Market Segmentation
12.1. By Regions
12.1.1. North America:(U.S. and Canada), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.2. Europe: (Germany, UK, France, Italy, Spain, and Rest of Europe), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.3. Asia-Pacific: (China, India, Japan, Australia and Rest of Asia Pacific), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.4. Latin America: (Brazil, Mexico, Rest of Latin America), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.5. Middle East and Africa, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2. By Product: Market Share (2020-2030F)
12.2.1. Stem cell therapy, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.2. Biomaterial, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.3. Tissue Engineering, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.4. Others, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3. By Application: Market Share (2020-2030F)
12.3.1. Bone Graft substitutes, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.2. Osteoarticular Diseases, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.3. Dermatology, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.4. Cardiovascular, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.5. Central Nervous System, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.6. Others, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4. By End-User: Market Share (2020-2030F)
12.4.1. Hospitals, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4.2. Special Clinics, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4.3. Others, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
13. Company Profile
13.1. 3M
13.1.1. Company Overview
13.1.2. Company Total Revenue (Financials)
13.1.3. Market Potential
13.1.4. Global Presence
13.1.5. Key Performance Indicators
13.1.6. SWOT Analysis
13.1.7. Product Launch
13.2. Novartis AG
13.3. Aspect Biosystems
13.4. Kite Pharma
13.5. Misonix
13.6. Takeda Pharmaceutical Company Limited
13.7. Tego Science
13.8. Vericel Corporation
13.9. Smith & Nephew plc
13.10. Anterogen Co., Ltd
13.11. Bluebird bio
Consultant Recommendation
**The above-given segmentations and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.